FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4236088596> ?p ?o ?g. }

• W4236088596 endingPage "1040" @default.
• W4236088596 startingPage "1039" @default.
• W4236088596 abstract "We read with interest the letter of Drs. Xia and Luo regarding our recent article on the cardioprotective effects of volatile anesthetic agents in elderly high-risk coronary artery patients. 1The authors propose an interesting hypothesis, which is that the use of propofol as sedation in the postoperative period on the intensive care unit may have added to the cardioprotective effects observed with sevoflurane and desflurane. Postischemic reperfusion is associated with an acute inflammatory response, involving a number of mediators, which ultimately may trigger cardiomyocyte death within the first hours after reperfusion. Drs. Xia and Luo propose that the potential of propofol in reducing cytokines and reactive oxygen species induced myocardial injury during reperfusion is responsible for the additional cardioprotective effect. It should be noted, however, that in our study, propofol administration was only started after arrival in the intensive care unit. This implies that in the sevoflurane and desflurane groups, during the first period of reperfusion (from the opening of the proximal anastomoses until the end of the operation), anesthesia was still obtained with the volatile anesthetic. If the beneficial effects of propofol during the first 2 h of reperfusion are assumed to be of major importance in the cardioprotective effects observed in the sevoflurane and desflurane groups, one would expect this effect also to be present in the propofol group, which was not the case in our study protocol.Different research groups have demonstrated that propofol has antioxidant activity and may even inhibit tumor necrosis factor α–induced human (umbilical vein) endothelial cell apoptosis, 2but the clinical relevance of these properties for myocardial protection remains to be established. Until now, all data published on the cardioprotective effects of propofol were obtained at higher concentrations than those used in clinical practice. For example, the cardioprotective effects observed by Ko et al. 3were obtained at propofol concentrations of 100 μm. Similarly, in the study of Xia et al. 4in isolated rat hearts, the enhanced ischemic tolerance of middle-aged rats was observed with a propofol perfusion at 12 μg/ml during the first 15 min of reperfusion, which was subsequently reduced to 5 μg/ml. Ebel et al. , 5on the contrary, found no effect of propofol on reperfusion injury when it was administered at concentrations of 1 μg/ml.The pathophysiology of myocardial reperfusion injury is extremely complex, with several pathways involved, ultimately resulting in myocardial dysfunction. As such, it is conceivable that different therapeutic interventions may act at different levels and have an additive cardioprotective effect. In addition to their pharmacologic preconditioning effect, volatile anesthetics also seem to have cardioprotective effects when administered only during the reperfusion period. 6,7Although the underlying mechanisms for these effects remain to be elucidated, there is now evidence that a reduction in postischemic adhesion of neutrophils may be involved. 8,9At the moment, it remains an open question how all these experimental observations may translate to clinical pathophysiology and even more to clinical treatment of myocardial ischemia–reperfusion injury.Therefore, although it is conceptually attractive, the hypothesis proposed by Drs. Xia and Luo lacks experimental and clinical evidence. To date, there are indeed no published data available supporting the hypothesis that the administration of propofol as a sedative in the intensive care unit contributes to the cardioprotective effects of peri-operatively administered sevoflurane and desflurane. Elucidation of this question would require a study protocol comparing sedation in the intensive care unit with propofol to another sedative agent without antioxidant properties." @default.
• W4236088596 created "2022-05-12" @default.
• W4236088596 creator A5037593049 @default.
• W4236088596 creator A5059097524 @default.
• W4236088596 date "2004-04-01" @default.
• W4236088596 modified "2023-10-17" @default.
• W4236088596 title "Sevoflurane or Desflurane Anesthesia plus Postoperative Propofol Sedation Attenuates Myocardial Injury after Coronary Surgery in Elderly High-risk Patients: In Reply" @default.
• W4236088596 doi "https://doi.org/10.1097/00000542-200404000-00051" @default.
• W4236088596 hasPublicationYear "2004" @default.
• W4236088596 type Work @default.
• W4236088596 citedByCount "1" @default.
• W4236088596 crossrefType "journal-article" @default.
• W4236088596 hasAuthorship W4236088596A5037593049 @default.
• W4236088596 hasAuthorship W4236088596A5059097524 @default.
• W4236088596 hasBestOaLocation W42360885961 @default.
• W4236088596 hasConcept C126322002 @default.
• W4236088596 hasConcept C164705383 @default.
• W4236088596 hasConcept C2776277131 @default.
• W4236088596 hasConcept C2776376669 @default.
• W4236088596 hasConcept C2776442465 @default.
• W4236088596 hasConcept C2776814716 @default.
• W4236088596 hasConcept C2778162923 @default.
• W4236088596 hasConcept C2778891214 @default.
• W4236088596 hasConcept C2780114680 @default.
• W4236088596 hasConcept C2781453256 @default.
• W4236088596 hasConcept C2908650173 @default.
• W4236088596 hasConcept C42219234 @default.
• W4236088596 hasConcept C541997718 @default.
• W4236088596 hasConcept C71924100 @default.
• W4236088596 hasConceptScore W4236088596C126322002 @default.
• W4236088596 hasConceptScore W4236088596C164705383 @default.
• W4236088596 hasConceptScore W4236088596C2776277131 @default.
• W4236088596 hasConceptScore W4236088596C2776376669 @default.
• W4236088596 hasConceptScore W4236088596C2776442465 @default.
• W4236088596 hasConceptScore W4236088596C2776814716 @default.
• W4236088596 hasConceptScore W4236088596C2778162923 @default.
• W4236088596 hasConceptScore W4236088596C2778891214 @default.
• W4236088596 hasConceptScore W4236088596C2780114680 @default.
• W4236088596 hasConceptScore W4236088596C2781453256 @default.
• W4236088596 hasConceptScore W4236088596C2908650173 @default.
• W4236088596 hasConceptScore W4236088596C42219234 @default.
• W4236088596 hasConceptScore W4236088596C541997718 @default.
• W4236088596 hasConceptScore W4236088596C71924100 @default.
• W4236088596 hasIssue "4" @default.
• W4236088596 hasLocation W42360885961 @default.
• W4236088596 hasOpenAccess W4236088596 @default.
• W4236088596 hasPrimaryLocation W42360885961 @default.
• W4236088596 hasRelatedWork W103037484 @default.
• W4236088596 hasRelatedWork W1977033487 @default.
• W4236088596 hasRelatedWork W2035279835 @default.
• W4236088596 hasRelatedWork W2047129791 @default.
• W4236088596 hasRelatedWork W2264653584 @default.
• W4236088596 hasRelatedWork W2319762082 @default.
• W4236088596 hasRelatedWork W2484880552 @default.
• W4236088596 hasRelatedWork W2894614916 @default.
• W4236088596 hasRelatedWork W2909242796 @default.
• W4236088596 hasRelatedWork W3133135983 @default.
• W4236088596 hasVolume "100" @default.
• W4236088596 isParatext "false" @default.
• W4236088596 isRetracted "false" @default.
• W4236088596 workType "article" @default.